Is Strand AI profitable?

No. Strand AI is a pre-seed startup with no disclosed revenue, ARR, or named customers as of July 2026. It has raised only $500K in pre-seed funding led by Y Combinator and has 1-10 employees, making profitability a distant question.

Who is Strand AI's biggest competitor?

Tempus AI, a ~$10B public precision-medicine company, is Strand AI's main threat. Tempus already owns paired multimodal patient datasets, acquired Deep 6 AI in March 2025, and shipped its own Patient Query AI agent by May 2026.

Could Tempus AI just replicate Strand AI's technology?

Yes, per third-party commentary from May 2026, Strand's multimodal imputation architecture is replicable by a competent team with about $20M and 18 to 24 months, and Tempus already owns the multimodal patient data Strand would need to train competitive models.

What does Strand AI actually build?

Strand AI builds multimodal foundation models that predict or impute missing biological data, such as gene expression, proteomics, and spatial transcriptomics, from whatever patient data is already available, aimed at pharma clinical trial cohort selection and biomarker discovery.

Has Strand AI landed any pharma customers?

As of July 27, 2026, no signed pharma partnerships, validation studies, or regulatory filings had been found for Strand AI. The company remains pre-revenue with no named customers despite launching publicly via Y Combinator in February 2026.

Strand AI is privately held and founder-owned with no parent company. It raised a $500K pre-seed round led by Y Combinator, and no priced valuation or subsequent funding rounds had been publicly disclosed as of July 2026.

YC Winter 2026 · United States

Strand AI

Builds AI models that predict missing patient biology data for pharma trials.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from within 12 months (by mid 2027) · Every call on the record Checkpoint: Landing a first named pharma design partner with a co-run validation study

The call

Strand AI has a real idea and no customers yet, racing a data-rich public rival before anyone validates the model on real trials.

Strand AI uses artificial intelligence to fill in missing patient information instead of running expensive lab tests. The problem: Tempus AI, a much larger public company worth $10 billion, already has the patient data Strand needs and the relationships with drug companies to sell competing products. Strand could win only if it signs a major pharmaceutical customer willing to test its system and publish results proving it works before Tempus copies the technology (which experts say takes 18 to 24 months). Right now Strand has zero named customers and zero published proof, so the clock is ticking hard.

Why

AI pressure: Well-funded teams replicating its imputation architecture. No proprietary data lock exists; a competent team could rebuild the model for about $20M in 18-24 months, per outside estimate. Could AI do the core job? Yes, likely.

Bigger players: Tempus AI (~$10B, public). Tempus owns the paired multimodal patient data Strand would need and could add imputation as an upsell to its existing assay business. Could a giant copy it? Yes, easily.

What protects it. Only its head start on the problem and founders' spatial biology background from Enable Medicine; no data or trust barrier yet exists.

What would change this call

Strand AI announces a named pharma design partner or pilot contract within 12 months. Shows Strand is building the trust-ladder proof needed to compete with Tempus's data lead.
Tempus AI ships a validated imputation or prediction feature on its multimodal platform. Shows the incumbent closed the window before Strand secured any validation.
A competing seed-stage team ships a similar imputation model with a paying pharma customer. Confirms the architecture is easily replicable and Strand's lead is not defensible.

Key numbers

$500K pre-seed round led by Y Combinator (2026-02-25)
Tempus AI valued at roughly $10B, public (2026-07-27)
Rival build estimated at $20M, 18-24 months (2026-05-01)

Named risks

No named pharma customers, validation studies, or regulatory filings as of July 2026. Severity: high
Tempus AI already owns paired multimodal patient data needed to train competitive imputation models. Severity: high
Architecture reportedly replicable by competent team with ~$20M in 18-24 months. Severity: high
Hallucinated biomarker prediction could cause a pharma trial informed by the model to fail. Severity: high
Extremely small team (1-10 people) with only $500K raised limits execution speed. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Tempus AI	losing to	Owns paired multimodal patient data; acquired Deep 6 AI March 2025; shipped Patient Query agent by May 2026
Enable Medicine	contesting	Founders' prior employer; direct technical peer in spatial multimodal biology data
Pathos AI	contesting	CEO's prior employer; Tempus-affiliated oncology foundation-model builder
TriNetX	losing to	Federated real-world-data network consolidating trial-feasibility market as of March 2026

Questions people ask

Is Strand AI profitable?: No. Strand AI is a pre-seed startup with no disclosed revenue, ARR, or named customers as of July 2026. It has raised only $500K in pre-seed funding led by Y Combinator and has 1-10 employees, making profitability a distant question.
Who is Strand AI's biggest competitor?: Tempus AI, a ~$10B public precision-medicine company, is Strand AI's main threat. Tempus already owns paired multimodal patient datasets, acquired Deep 6 AI in March 2025, and shipped its own Patient Query AI agent by May 2026.
Could Tempus AI just replicate Strand AI's technology?: Yes, per third-party commentary from May 2026, Strand's multimodal imputation architecture is replicable by a competent team with about $20M and 18 to 24 months, and Tempus already owns the multimodal patient data Strand would need to train competitive models.
What does Strand AI actually build?: Strand AI builds multimodal foundation models that predict or impute missing biological data, such as gene expression, proteomics, and spatial transcriptomics, from whatever patient data is already available, aimed at pharma clinical trial cohort selection and biomarker discovery.
Has Strand AI landed any pharma customers?: As of July 27, 2026, no signed pharma partnerships, validation studies, or regulatory filings had been found for Strand AI. The company remains pre-revenue with no named customers despite launching publicly via Y Combinator in February 2026.
Who owns Strand AI?: Strand AI is privately held and founder-owned with no parent company. It raised a $500K pre-seed round led by Y Combinator, and no priced valuation or subsequent funding rounds had been publicly disclosed as of July 2026.

Timeline

2026-05-01Third-party commentary piece frames Strand as unvalidated model racing Tempus on data and trust
2026-05Tempus AI ships Patient Query, an AI agent for trial patient matching
2026-03-12CTO Oded Falik gives technical interview on cross-modal prediction approach
2026-02-25Strand AI publicly debuts via Launch YC as data layer for biology
2025-03Tempus AI acquires Deep 6 AI, an NLP-driven patient-matching platform
2025Strand AI founded
2024-12-20Microsoft publishes BiomedCLIP, a multimodal biomedical foundation model, showing academic precedent

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company